Genentech's leukemia drug obinutuzumab shows promise in trial

02/1/2013 | American City Business Journals · OncLive

Treatment-naive patients with chronic lymphocytic leukemia who took Genentech's experimental drug GA-101, or obinutuzumab, in combination with chlorambucil, survived significantly longer without their disease worsening compared with patients who took chlorambucil alone, a late-stage trial found. Genentech plans to submit this trial's data to U.S. and European regulators for potential approval.

View Full Article in:

American City Business Journals · OncLive

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ